6533b861fe1ef96bd12c4e42

RESEARCH PRODUCT

Inhalable polymer-glycerosomes as safe and effective carriers for rifampicin delivery to the lungs

José E. PerisDonatella ValentiEnrica BullitaMaria Letizia MancaMaria Cristina CardiaAnna Maria FaddaMaria ManconiVirginia MelisElena TamburiniInes Castangia

subject

GlycerolMaleDrugStaphylococcus aureusCell SurvivalPolymersmedia_common.quotation_subjectSodium hyaluronateMicrobial Sensitivity Tests02 engineering and technologyPharmacology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineColloid and Surface ChemistryMicroscopy Electron TransmissionIn vivoAdministration InhalationGlycerolmedicineAnimalsHumansTissue DistributionRats WistarPhysical and Theoretical ChemistryAntibiotics AntitubercularLungmedia_commonDrug CarriersLiposomeVesicleSurfaces and InterfacesGeneral Medicine021001 nanoscience & nanotechnologychemistryA549 CellsLiposomesNanoparticlesRifampin0210 nano-technologyDrug carrierRifampicinBiotechnologymedicine.drug

description

Rifampicin loaded glycerosomes, vesicles composed of phospholipids, glycerol and water, were combined with trimethyl chitosan chloride (TMC) to prepare TMC-glycerosomes or, alternatively, with sodium hyaluronate (HY) to obtain HY-glycerosomes. These new hybrid nanovesicles were tested as carriers for pulmonary delivery of rifampicin. Glycerosomes without polymers were also prepared and characterized. All vesicles were similar: they were spherical, multilamellar and able to incorporate good amount of rifampicin (EE%∼55%). The addition of the polymers to the formulations allowed an increase of mean diameter. All the glycerosomes, in particular HY-glycerosomes, were able to deliver the drug to the furthest stages of the Next Generation Impactor and the aptitude of the vesicles to be nebulized was always higher than that of drug dispersion. Rifampicin nanoincorporation in vesicles reduced the in vitro drug toxicity on A549 cells, as well as increased its efficacy against Staphylococcus aureus. Finally, the in vivo biodistribution and accumulation, evaluated after intra-tracheal administration to rats, confirmed the improvement of rifampicin accumulation in lungs.

https://doi.org/10.1016/j.colsurfb.2016.03.044